Xencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026
PUBT · 5d ago
Share
Listen to the news
- Xencor flagged Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma for a proffered oral presentation at ESMO 2026.
- Abstract scheduled for release on Oct. 18 at 3:05 p.m. PDT; presentation slated for the Oct. 23-27 congress in Madrid.
- Program positioned to support dose selection for a planned Phase 3 pivotal study in advanced clear cell renal cell carcinoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xencor Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260716029119) on July 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved